A simple architecture with self-assembled monolayers to build immunosensors for detecting the pancreatic cancer biomarker CA19-9 by Soares, Andrey Coatrini et al.
This is an Accepted Manuscript, which has been through the  
Royal Society of Chemistry peer review process and has been 
accepted for publication.
Accepted Manuscripts are published online shortly after 
acceptance, before technical editing, formatting and proof reading. 
Using this free service, authors can make their results available 
to the community, in citable form, before we publish the edited 
article. We will replace this Accepted Manuscript with the edited 
and formatted Advance Article as soon as it is available.
You can find more information about Accepted Manuscripts in the 
author guidelines.
Please note that technical editing may introduce minor changes 
to the text and/or graphics, which may alter content. The journal’s 
standard Terms & Conditions and the ethical guidelines, outlined 
in our author and reviewer resource centre, still apply. In no 
event shall the Royal Society of Chemistry be held responsible 
for any errors or omissions in this Accepted Manuscript or any 
consequences arising from the use of any information it contains. 
Accepted Manuscript
rsc.li/analyst
Analyst
www.rsc.org/analyst
ISSN 0003-2654
PAPER
Michele Zagnoni et al. 
Emulsion technologies for multicellular tumour spheroid radiation assays
Volume 141 Number 1 7 January 2016 Pages 1–354
Analyst
View Article Online
View Journal
This article can be cited before page numbers have been issued, to do this please use:  A. C. Soares, J. C.
Soares, F. M. Shimizu, V. D. C. Rodrigues, I. T. Awan, M. E. Melendez, M. H. D. O. Piazzetta, A. L. Gobbi, R.
M. Reis, J. H. T. G. Fregnani, A. L. Carvalho and O. N. Oliveira Jr., Analyst, 2018, DOI:
10.1039/C8AN00430G.
Analyst  
ARTICLE 
This journal is © The Royal Society of Chemistry 20xx J. Name., 2018, 00, 1-3 | 1 
Please do not adjust margins 
Please do not adjust margins 
a.
 São Carlos Institute of Physics, University of São Paulo, São Carlos, Brazil. 
b.
 Department of Materials Engineering, São Carlos School of Engineering, 
University of São Paulo, São Carlos, Brazil. 
c.
 Brazilian Nanotechnology National Laboratory, Brazilian Center for Research in 
Energy and Materials, Campinas, Brazil.  
d.
 Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil. 
e.
 Life and Health Sciences Research Institute (ICVS), School of Health Sciences, 
University of Minho, Braga, Portugal. 
f.
 ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal. 
 
Electronic Supplementary Information (ESI) available: Cyclic Voltammograms for 
film architectures, AFM images of functionalized electrodes, Calibration curves 
obtained from PM-IRRAS spectra, Parallel coordinates plot for the capacitance 
spectra of CA19-9 commercial samples and tables of quantifications of cells and 
patients samples. See DOI: 10.1039/x0xx00000x 
Received  
Accepted  
DOI: 10.1039/x0xx00000x 
www.rsc.org/ 
A simple architecture with self-assembled monolayers to build 
immunosensors for detecting the pancreatic cancer biomarker 
CA19-9 
Andrey Coatrini Soares*a,b, Juliana Coatrini Soares a, Flavio Makoto Shimizu a,c, Valquiria da Cruz 
Rodrigues a, Iram Taj Awan a, Matias Eliseo Melendez d, Maria Helena Oliveira Piazzetta c, Angelo 
Luiz Gobbi c, Rui Manuel Reis d,e,f, José Humberto T. G. Fregnani d, André Lopes Carvalho d and 
Osvaldo N. Oliveira Jr a. 
 
The challenge of early diagnosis of pancreatic cancer in routine clinical practice requires low-cost means of detection, and 
this may be achieved with immunosensors based on electrical or electrochemical principles. In this paper, we report on a 
potentially low-cost immunosensor built with interdigitated gold electrodes coated with a self-assembled monolayer and a 
layer of anti-CA19-9 antibodies, which is capable of detecting the pancreatic cancer biomarker CA19-9 using electrical 
impedance spectroscopy. Owing to specific, irreversible adsorption of CA19-9 onto its corresponding antibody, according 
to data from polarization-modulated infrared reflection absorption spectroscopy (PM-IRRAS), the immunosensor is highly 
sensitive and selective. It could detect CA19-9 in commercial samples with a limit of detection of 0.68 U/mL, in addition to 
distinguishing between blood serum samples from patients with different concentrations of CA19-9. Furthermore, treating 
the capacitance data with information visualization methods we were able to verify the selectivity and robustness of the 
immunosensor with regard to false positives, as the samples containing higher CA19-9 concentrations, including from 
tumor cells, could be distinguished from those with possible interferents. 
Introduction 
Early diagnosis is crucial for increasing survival rates and life 
expectancy for cancer patients, particularly for pancreatic 
cancer for which clinical symptoms are normally inexistent 
before the tumor is at an advanced stage
1
. The challenge is 
then to provide low-cost point-of-care methods for routine 
blood or urine tests, which requires identification of suitable 
biomarkers. For pancreatic cancer, the antigen CA19-9, a 
glycoprotein synthesized by human pancreatic and biliary duct 
cells
2
, is frequently used as a clinical biomarker
3
. Because 
there is a corresponding specific antibody, immunosensors can 
be built and CA19-9 is usually detected with the Enzyme Linked 
Immuno Sorbent Assay (ELISA). This method, however, 
involves high cost and has limited sensitivity that may hamper 
its use for detecting cancer at early stages
4
. This has motivated 
significant research into immunosensors based on 
electrochemical and impedance spectroscopy principles of 
detection
5,6
. These sensors are made with films of materials 
organized at the nanoscale where organized, tailored 
structures lead to successful nanotechnologies
7
. Typically, 
these nanostructures contain a suitable matrix for effective 
immobilization of the antibodies, and are fabricated with 
experimental techniques that allow for control of molecular 
architectures
8
. Examples of such techniques are the Langmuir-
Blodgett (LB)
9
, layer-by-layer (LbL)
10–12
 and the self-assembled 
monolayer (SAM)
13,14
 techniques, which assist in preserving 
the structural integrity of biomolecules and communication 
with electrodes
12,15
.  
 In developing these immunosensors, the main goals have 
been associated with seeking synergy in the materials chosen 
for the matrix and in the identification of the detection 
method, including data analysis, in order to yield high 
sensitivity and selectivity toward CA19-9. Examples of film 
architectures include chitosan/concanavalin A
16
,  
poly(ethyleneimine)/carbon nanotubes
8,17
, carbon-based 
materials
8
, electrospun nanofibers
18
 and polythionine-Au 
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composites
19
. While the combination of nanomaterials in some 
cases provides superior performance, incorporation of various 
components turns the fabrication procedures more complex 
and expensive. As for detection, methods related to 
electrochemistry
18,20,21
, chemiluminescence
22
, 
piezoelectricity
23
, surface plasmon resonance
24,25
 and 
impedance spectroscopy
17,26
 have been used.  
 In this study, we produced immunosensors with one of the 
simplest architectures possible to immobilize the anti-CA19-9 
antibodies, i.e. the sensing units had the active layer adsorbed 
on a SAM activated with N-hydroxisuccinimide (NHS) and 
ethyl-3-(3-dimethyllaminopropyl) carbodiimide(EDC). In spite 
of this simplicity, the immunosensing performance was 
competitive with similar, more sophisticated sensors. Indeed, 
compared to previous contributions16–18, including from our 
own group, the novelty in the present study lies mainly in the 
fabrication of a potentially low-cost immunosensor with 
simpler architecture that is able not only to detect low 
concentrations of CA19-9 in commercial samples, but also 
distinguish between blood serum samples from patients of a 
cancer hospital with varied CA19-9 concentrations. This was 
made possible by treating the impedance spectroscopy data 
with information visualization methods27–29, which have not 
been exploited to the extent they should in the biosensing 
field. 
Experimental  
Electrode Modification. 
 
Detection of CA19-9 protein was performed with an 
immunosensor made with an active layer of anti-CA19-9 (Aviva 
System Biology, USA) deposited on a self-assembled 
monolayer (SAM) of 11-mercaptoundecanoic acid (11-MUA) 
on gold interdigitated electrodes fabricated onto BK7 
substrates. The electrodes had 50 pairs of fingers, 10 μm wide 
and spaced 10μm away from each other. Deposition of 11-
MUA was made by immersing the interdigitated electrode into 
a 5mmol/L solution for 8h, followed by activation of the 11-
MUA carboxylic acid groups by immersion into 0.1 M N-
hydroxisuccinimide (NHS) (Sigma-Aldrich, USA) and 0.1 M 
ethyl-3-(3-dimethyllaminopropyl) carbodiimide(EDC) (Sigma-
Aldrich, USA) for 30 min. A layer of anti-CA19-9 was adsorbed 
by immersion in 20µL of antibody solution at 37ºC during 45 
min, and the biosensor architecture was completed by 
immersion into an aqueous solution of 1% bovine serum 
albumin (BSA) (Sigma-Aldrich, USA) to block non-specific active 
sites. After each step, electrodes were washed with ethanol 
and ultrapure water to remove non-adsorbed molecules. 
Figure 1 shows a schematic picture of the immunosensor 
architecture. 
 
Figure 1: Immunosensor architecture containing an 11-MUA 
monolayer and immobilized antibodies for detecting the CA19-9 
protein. 
Film Characterization. 
The nanostructured films used to functionalize the electrodes 
were characterized using cyclic voltammetry and atomic force 
microscopy (AFM). Cyclic voltammetry, in particular, was used 
to optimize the fabrication conditions for the matrix layer of 
11-MUA. Gold electrodes (~0.25 cm
2
) were immersed in 11-
MUA solution for 1, 8, 12 and 24 h, washed in ethanol to 
remove non-adsorbed molecules, dried for 2h at 25ºC and 
placed in the electrochemical cell, which had an Ag/AgCl 
reference electrode and platinum counter electrode (0.5 cm²). 
A sweep potential was applied between −0.2 V and 0.7 V at a 
scan rate of 50 mV/s in 5 mmol/L [Fe(CN)6]
-3
/[Fe(CN)6]
-4
 
solution. All measurements were carried out with a 
potentiostat Autolab PGSTAT 204 (Metrohm, Switzerland). An 
AFM instrument from Bruker (USA), model Dimension 
FastScan, was used to investigate the morphology of the 
nanostructured films deposited on the interdigitated 
electrodes in the tapping mode with scan rate of 0.6 Hz. 
Detection of CA19-9 Protein 
The CA19-9 protein (Aviva System Biology, USA) was detected 
using electrical impedance spectroscopy with a Solartron 
model SI 1260 A (Solartron Analytical, USA), in the range 
between 10
2
 and 10
6
Hz, with immunosensors built as 
described above. Immunosensors were first exposed to CA19-9 
commercial samples at 37 U/mL during 0, 1, 2, 4, 6, 8, 10, 12, 
14 and 15 min to optimize the adsorption time of the 
biomarkers. Then different concentrations of CA19-9 
commercial samples (0, 0.1, 4, 6, 16, 41, 78, 115, 152 and 189 
U/mL) were dropped on the functionalized electrodes, 
followed by washing in ultrapure water and immersion in a 
phosphate buffered saline (PBS) solution to acquire the 
capacitance spectra. The data collected were used to construct 
the calibration curves and calculate the limit of detection. A 
series of control experiments was performed with ascorbic 
acid (AA) (Sigma-Aldrich, USA), uric acid (UA) (Sigma-Aldrich, 
USA), biomarker p24 (p24) (Bio-Synthesis Inc, USA), CA19-9 in 
fetal bovine serum (FBS) and two cell lines supernatant 
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samples, HT-29 (containing 12.26 U/mL of CA19-9) and SW-
620 (with no detectable levels of CA19-9). These cell lines, 
obtained from Barretos Cancer Hospital, were maintained in 
Dulbecco’s modified eagle’s medium (DMEM) and RPMI 1640, 
containing 10% fetal bovine serum (FBS), 1% 
penicillin/streptomycin and 2 mM glutamine in a humidified 
5% CO2 incubator at 37 °C. PBS buffer was used to wash the 
cells lines, followed by cultivation in OptiMEM media, without 
serum. After 48 h, the supernatant was filtered and stored at 
−80°C for further quanSﬁcaSon of CA19-9. For gold-standard 
quantification, we use an electrochemiluminescence 
immunoassay (ECLIA) in a commercially available kit in 
Cobas601 (Roche Diagnostics, USA). The calibration curve was 
calculated with Elecsys CA19−9 CalSet (Roche DiagnosScs, 
USA). 
Samples from eight patients diagnosed with pancreatic 
cancer were also analyzed using electrical impedance 
measurements. The immunosensor was immersed in the 
serum of eight patients, with unknown CA19-9 concentration, 
during 10 min for CA19-9 protein adsorption. The 
characteristics of the patient samples are summarized in Table 
S1 in Electronic Supplementary Material. 
 
 
Information Visualization for Biosensing. 
 
Biosensing data are commonly treated using statistical 
methods that reduce their dimensionality, with Principal 
Component Analysis (PCA)30 being perhaps the most common 
method. Optimization of immunosensing performance may be 
reached by applying other information visualization methods 
that allow for a detailed evaluation of the data, especially 
when feature selection is desired. For sensors based on 
impedance spectroscopy this is particularly relevant because 
the electrical response varies significantly with the frequency 
of the applied field, and sensing events may occur preferably 
at specific frequency ranges. Indeed, when sensing depends on 
changes of the electrical double layer formed at a solid/liquid 
interface on a charged surface, the low frequency region (100 
Hz or less) is the most relevant. Here we processed the 
capacitance spectra using a free software suite referred to as 
PEx-Sensors
29
, which implements projection techniques that 
use interactive maps in 2-D (IDMAP) and parallel coordinates 
(PC)
31
.In the PC technique
32
, the dataset is plotted on equally 
spaced coordinate axes scaled to depict the range of measured 
values. Capacitance values are inferred from the intersection 
of the value measured with the frequency axis, generating a 
visual representation that reveals the distribution of the data 
and their correlations
29
. We also used IDMAP which considers 
Euclidean distances between the signals of different samples X 
= {x1, x2, x3, …,xn) and projects these data instances into a 
lower-dimension space, where Y = {y1, y2, y3, …, yn) is the 
position of visual elements. For IDMAP, the error functions are 
calculated using an injective function, which considers the 
maximum maxδ and minimum minδ distances between data 
instances, the distance between two samples in original space 
( )
ji xx ,δ  and the distance function on the projected space
( )ji yyd , . This function minimizes the term 
( ) ( ) Xxxxfxfdxx jijiji ∈∀− ,)(),(,δ   and is given by eq. 1. 
( )
( )ji
ji
IDMAP yyd
xx
S ,
,
minmax
min
−
−
−
=
δδ
δδ
 
Results and Discussion 
Monitoring Electrode Functionalization with Nanostructured 
Films. 
 
Optimization of SAM fabrication was performed based on the 
cyclic voltammetry results in Figure S1 in the Electronic 
Supplementary Information where the [Fe(CN)6]
-3
/[Fe(CN)6]
-4
 
redox process was monitored. This process leads to reduction 
and oxidation peaks at 108 and 341mV, respectively, for the 
Au surface. The adsorption of an 11-MUA monolayer on the Au 
surface decreases electron exchange between the electrode 
and [Fe(CN)6]
-3
/[Fe(CN)6]
-4
 solution, thus limiting diffusion of 
the electroactive species and decreasing the current density in 
the redox peaks. This charge exchange becomes less 
pronounced for electrodes modified during 8h or more, i.e. 
this is the time required to cover the gold electrode surface. 
The 11-MUA coating was confirmed in the AFM images of 
Figure S2, which also show that the roughness of the sensing 
film varies with the deposition of the active layer of anti-CA19-
9 and then with the adsorption of CA19-9 mimicking a sensing 
experiment. More specifically, the root mean square 
roughness of the 11-MUA film was 5.1 nm, which increased to 
13.9 with the layer of anti-CA19-9 antibodies and then to 16.9 
nm after adsorption of CA19-9 molecules at high 
concentration. 
 The sensing mechanism, believed to be associated with 
specific adsorption of CA19-9 molecules on the anti-CA19-9 
layer, can actually be interrogated with PM-IRRAS, where the 
spectrum of the matrix (architecture 11-MUA/EDC/NHS) to 
immobilize anti-CA19-9 antibodies is used as reference. Figure 
2 shows a specific region of the PM-IRRAS spectra (see the 
entire spectra in Figure S3, and the procedure for baseline 
correction in Figure S4 in the Electronic Supplementary 
Material), with bands at 1550 cm
-1
 and 1655 cm
-1
 assigned to 
amide II and amide I groups
33,34
 present in both antibodies 
(anti-CA19-9) and antigens (CA19-9). The area and intensity of 
these bands increase with CA19-9 concentration, as expected. 
This can be seen in Figures S5 and S6 in the Electronic 
Supplementary Material for the bands assigned to amide 
groups, including C=O stretching, C-N stretching, and N-H 
bond
33,34
.  
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Figure 2: PM-IRRAS spectra of 11-MUA/EDC/NHS film modified 
with antibodies and different concentrations of CA19-9 
biomarkers. The spectrum for the architecture 11-
MUA/EDC/NHS was used as baseline. 
 
Detection of CA19-9 Protein 
 
The kinetics of adsorption of CA19-9 biomarkers on the 
immunosensor was studied to determine the optimized 
conditions for the experiments with distinct biomarker 
concentrations. Figure 3 shows the capacitance spectra 
obtained with the immunosensor (11-MUA/EDC/NHS/anti-
CA19-9) exposed to a 37 U/mL concentration of CA19-9 at 
various adsorption times. The increased adsorption can be 
represented by plotting the capacitance at a fixed frequency 
(we chose 1 kHz) versus time of adsorption, where the 
capacitance no longer increases above 48.24 nF according to 
the figure in the insert. This time dependence can be modeled 
with a double Langmuir-Freundlich function18, which may 
represent two adsorption processes of CA19-9 biomarker on 
the interdigitated electrodes modified with 11-
MUA/EDC/NHS/anti-CA19-9. Also inferred from the figure is 
that 8 min is the minimum time for reaching complete 
adsorption at a given CA19-9 concentration, and this was the 
adsorption time employed for the subsequent sensing 
experiments. 
 
Figure 3: Capacitance spectra taken at different adsorption 
times for CA19-9 biomarker on immunosensors made with 11-
MUA/EDC/NHS/anti-CA19-9. The insert shows the time 
dependence for the capacitance at 1 kHz, fitted with a double 
Langmuir-Freundlich equation. 
 
Detection of CA19-9 commercial samples in PBS, 
supernatant cell samples (HT-29 and SW-620), and CA19-9 
immersed in FBS (12.26 U/mL) was performed with impedance 
spectroscopy, thus generating the capacitance spectra in 
Figure 4. Changes in the spectra are more prominent at 
intermediate (1-10 kHz) and low frequency regions (0.1-1 kHz), 
because the sensor response is governed by specific 
interaction of the CA19-9 biomarker with the antibody 
immobilized on the electrode and the ensuing effect on the 
electrical double layer35,36 induced by such specific 
interactions. The increase in capacitance at 1 kHz with CA19-9 
concentration in the insert of Figure 4 can be fitted with a 
combination of Langmuir-Freundlich functions as in Eq. 2. 
 
 
                                                                                                   (2) 
 
 
where q is amount of adsorbed material on the substrate at 
equilibrium, Qsat1 and Qsat2 are adsorption capacities related to 
the number of available active sites, C is the analyte 
concentration at equilibrium, Ka1 and Ka2 are affinity constants 
for adsorption, and n1 and n2 are heterogeneity indices. The 
choice of 1 kHz as the frequency for this analysis was based on 
a subsidiary study in which the parallel coordinates technique 
was used to plot the capacitance data (see Figure S7 in the 
Electronic Supplementary Information), and from which we 
determined the highest silhouette coefficient for distinguishing 
similar samples32. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Capacitance spectra for 11-MUA/EDC/NHS/anti-
CA19-9 immunosensor immersed in PBS solutions with various 
concentrations of CA19-9 commercial samples, cell 
supernatant samples (HT-29 and SW-620) and CA19-9 
commercial sample immersed in FBS (12.26 U/mL). The insert 
shows the CA19-9 concentration dependence for the 
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capacitance at 1 kHz, which can be fitted with a double 
Langmuir-Freundlich function. 
 
The reason why there are two Langmuir-Freundlich processes, 
rather than one as is common in other immunosensors, cannot 
be determined with the present data. It is nevertheless 
consistent with the two-process fitting for the kinetics of 
adsorption in the inset of Figure 3. It may seem surprising that 
the simple Langmuir-Freundlich model should account for the 
changes in electrical response where many intermolecular 
interactions are involved. We speculate that this occurs 
because of the predominance of the antigen-antibody 
interactions, which are so strong to make all the other 
interactions irrelevant when modeling the concentration 
dependence of the electrical response. Since the plot in the 
insert of Figure 4 is not linear, we took an extrapolation of the 
low concentration region and used the IUPAC method to 
determine the limit of detection of 0.68 U/mL, which is 
comparable to similar immunosensors16 and competitive with 
Elecsys commercial tests37. Significantly, this level of sensitivity 
is sufficient for clinical diagnosis since the reference value for 
patients with pancreatic cancer is 37 U/mL38,39. Furthermore, 
supernatant of HT-29 cells and CA19-9 immersed in FBS (12.26 
U/mL) were considered similar to commercial samples from 
the 6-16 U/mL region, while the SW-620 supernatant cells and 
FBS samples showed similarity to samples from the 0-0.1 U/mL 
region. The quantifications of these samples using 
electrochemiluminescence are given in Table S2 in the 
Electronic Supplementary Material. 
 The excellent performance in detecting CA19-9 in cell 
supernatant and in protein immersed in FBS samples served as 
motivation to investigate whether the immunosensor would 
also be capable of distinguishing samples of human blood 
serum from eight patients (Ethics Committee Number: 
1.447.041). This was done by projecting the capacitance 
spectra using the IDMAP technique, with which similar spectra 
should be projected close to each other on the 2D IDMAP plot. 
Figure 5 indeed shows clear distinction for the blood serum 
with different CA19-9 concentrations. More importantly, the 
group of patients with CA19-9 concentration above 37U/mL is 
clearly discriminated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Capacitance data in triplicate projected on an IDMAP 
plot, which were obtained from sensing experiments with 
blood serum samples from eight patients (labeled as P1 
through P8). The clusters were established from 
measurements in blind tests. The labels with the 
concentrations obtained in electrochemiluminescence 
immunoassays (ECLIA), as described in the Experimental 
Section, were included at the end of the plotting procedure. 
 
In addition to reaching a high sensitivity, one of the most 
important features of immunosensors is selectivity, in order to 
avoid false positives (or false negatives). We tested the 
selectivity of the 11-MUA/EDC/NHS/anti-CA19-9 
immunosensor in two types of control experiments. Figure S8 
in the Supplementary Material shows that the capacitance at a 
fixed frequency is not altered upon changing the concentration 
of CA19-9 biomarker when the sensing unit does not contain 
an active layer of anti-CA19-9 antibodies, in contrast to the 
expected increase in capacitance for the immunosensor made 
with such an active layer. In the second type of control 
experiments, the immunosensor was exposed to cell 
supernatants samples (HT-29 and SW-620), analytes present in 
blood including ascorbic acid (AA), uric acid (UA), and fetal 
bovine serum (FBS), in addition to another biomarker for HIV 
(p24). Figure 6 shows the IDMAP plot for the capacitance 
spectra. On the right hand side are the samples with no (or 
very small) CA19-9 concentrations, including the buffer 
solutions, commercial samples, the non-specific analytes and 
the SW620 cells. The samples containing CA19-9 are placed 
progressively to the left as the protein concentration 
increases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: IDMAP for the capacitance spectra of CA19-9 
commercial samples, cell supernatants (HT-29 and SW-620), 
CA19-9 immersed in fetal bovine serum (FBS), and non-specific 
analytes (AU, AA, p24). The data for the blood serum samples 
shown in Figure 5 were not included in this figure because the 
electrical response of the serum samples differs considerably 
and the corresponding data points would be positioned far 
away from the other data points 
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Conclusions 
 
A relatively simple film architecture has been used to fabricate 
immunosensors to detect the biomarker CA19-9, using 
Electrical Impedance Spectroscopy. This detection method is 
advantageous because it allows for electrode miniaturization, 
no need to employ electroactive molecules and reference 
electrodes. Though the immunosensor had only a self-
assembled monolayer coated with the active layer of anti-
CA19-9 antibodies, being simpler than in previous works, it 
was sufficiently sensitive with a limit of detection of 0.68 U/mL 
in order to apply for early diagnosis of pancreatic cancer. In 
addition, by treating the capacitance data with 
multidimensional projection techniques, it has been possible 
to discriminate blood serum samples from patients which had 
distinct concentrations of CA19-9. Indeed, these experiments 
served as a proof-of-principle that patients likely to develop 
(or already developed) pancreatic cancer could be diagnosed 
in a simple, fast screening procedure.  
 The results from a series of control experiments confirmed 
the immunosensor robustness, with no false positives, proving 
that the high sensitivity arises solely from the antibody-antigen 
interaction. This interaction was actually investigated in detail 
using PM-IRRAS and verifying that the concentration 
dependence for the change in capacitance obeys a Langmuir-
Freundlich model with two combined functions. Together with 
reports from the recent literature, the results shown here 
confirm that the technology of immunosensors based on 
impedance spectroscopy is mature for introducing detection of 
CA19-9 in routine clinical practice. There are, however, 
important challenges to be faced before this type of 
immunosensor can be widely disseminated. The first challenge 
is associated with the required mass production of 
reproducible sensing units (test stripes), which can only be 
achieved with a systematic, diligent device engineering work. 
However, even with such a work it is probably not possible to 
fabricate sensing units with identical electrical responses – 
unlike the case of devices made with inorganic 
semiconductors. The task of establishing reliable detection 
ranges and calibration is therefore essential. The second 
challenge arises from the need of data analysis. If 
multidimensional projections are to be used, for example, 
different mappings will be generated when sensing units are 
replaced, so that some sort of calibration will be necessary. 
This has to be done via data processing with software to avoid 
extensive measurements to establish standards. A solution to 
this problem is not yet available, thus requiring integrated 
research by computer scientists and analytical chemists. 
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